Navigation Links
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
Date:6/9/2009

Anti-TNF Experienced Patients Demonstrated Improvement With Every-Four-Week Subcutaneous SIMPONI Despite Previous Medication or Reason for Discontinuation

COPENHAGEN, June 9 /PRNewswire/ -- A new analysis demonstrated that a greater proportion of patients with moderately to severely active rheumatoid arthritis (RA) who had prior treatment with anti-tumor necrosis factor (TNF)-alpha agents and received subcutaneous injections of SIMPONI(TM) (golimumab) once every four weeks experienced significant improvements in signs and symptoms through week 24, compared with patients receiving placebo. Patients continued to receive stable doses of methotrexate, sulfasalazine and/or hydroxychloroquine if receiving them at baseline. These data were presented at the 2009 European League Against Rheumatism (EULAR) Annual Congress.

Findings from the GOlimumab After Former anti-TNF Therapy Evaluated in RA (GO-AFTER) study, demonstrated that patients previously treated with adalimumab, etanercept or infliximab responded to and tolerated SIMPONI regardless of the type of prior anti-TNF therapy, as well as the number of prior therapies or reason for discontinuation. According to the study, 39 percent of patients receiving SIMPONI whose prior anti-TNF-alpha therapy had been discontinued due to a lack of efficacy achieved at least a 20 percent improvement in arthritis symptoms (ACR 20) at week 14, compared with 18 percent of patients receiving placebo (p<0.001). Thirty-four percent of patients receiving SIMPONI whose prior anti-TNF-alpha therapy had been discontinued for all other reasons achieved ACR 20, compared with 20 percent of patients receiving placebo (p=0.027).

"Golimumab has shown promise in the treatment of rheumatoid arthritis patients who have previously discontinued other anti-TNF-alpha therapies," said Josef S. Smolen, MD, Professor and Chairman, Departm
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
2. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
3. SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease
4. New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
5. New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
6. New Imaging Analysis Predicts Brain Tumor Survival
7. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
8. CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
9. SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease
10. CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals
11. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  El Camino Hospital, a leader in the ... the Leaf Patient Monitoring system to help prevent hospital-acquired ... patients susceptible to bed sores. The decision ... of the system, which showed dramatic improvement in compliance ... is the one of the most effect ways to ...
(Date:7/30/2014)... PISCATAWAY, N.J. , July 30, 2014  InnoPharma, ... for Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), ... of agitation and disturbed behaviors in patients with schizophrenia ... of this generic injectable drug, InnoPharma has entered into ... Sandoz Canada will make, use, sell, market ...
(Date:7/30/2014)... 30, 2014 Cynosure, Inc. (NASDAQ: ... treatments for non-invasive and minimally invasive applications, today announced that ... Operating Officer and Chief Financial Officer Timothy W. Baker ... Baker, 53, will continue to serve as CFO and will ... who remains Chairman and Chief Executive Officer. ...
Breaking Medicine Technology:El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2
... CITY, N.J., Nov. 14, 2011 /PRNewswire-Asia-First Call/ -- American ... Company" or "AOBO"), a pharmaceutical company dedicated to improving ... broad range of prescription and over the counter ("OTC") ... third quarter 2011 earnings conference call at 8:00 am ...
... Patients using Pradaxa (dabigatran), a new blood thinner aimed ... the treatment 17 percent of the time after the first ... Heart Association,s Scientific Sessions. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO ... a subsidiary of Medco Health Solutions, Inc. (NYSE: ...
Cached Medicine Technology:American Oriental Bioengineering to Hold Third Quarter 2011 Earnings Conference Call at 8:00 AM on November 15, 2011 2Medco Research Institute Study Shows Some Patients Discontinue New Anticoagulant Drug Early, Which May Increase Stroke Risk 2Medco Research Institute Study Shows Some Patients Discontinue New Anticoagulant Drug Early, Which May Increase Stroke Risk 3Medco Research Institute Study Shows Some Patients Discontinue New Anticoagulant Drug Early, Which May Increase Stroke Risk 4
(Date:7/30/2014)... -- Clues to whether a person is at risk for ... study suggests. Chemical changes to a gene involved in ... thoughts and behaviors, the study,s authors explained. Spotting those changes ... patient,s risk for suicide, they said. "Suicide is a ... in our prevention efforts because we have no consistent way ...
(Date:7/30/2014)... a protein that could help doctors decide which bladder ... radiotherapy more effective, according to a study* published in ... The team from The University of Manchester, funded by ... tumour had high levels of a protein, called ,HIF-1α, ... oxygen mixed with carbon dioxide gas and nicotinamide ...
(Date:7/30/2014)... Children diagnosed with depression as preschoolers are likely to ... new research shows. , Depressed preschoolers were 2.5 times ... and middle school than kids who were not depressed ... University School of Medicine in St. Louis. , Their ... American Journal of Psychiatry . , "It,s the ...
(Date:7/30/2014)... Europe commercial aviation actuation system market is estimated at ... reach $1,686.72 million by 2019 at a CAGR of ... of opportunities and challenges which will assume prominence in ... in the past, yet the sector has regained quickly, ... growth rate of approximately 5 % per year. Despite ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Effective ... is now accepting Highmark Blue Cross Blue Shield ... licensed dietetic nutritionist, Nourish Nutrition and Health opened ... downtown Pittsburgh, in Wexford. , The basis ... Health revolve around informing clients on the simplicity ...
Breaking Medicine News(10 mins):Health News:Could a Blood Test Predict Suicide Risk? 2Health News:Could a Blood Test Predict Suicide Risk? 3Health News:Scientists pinpoint bladder cancer patients who could benefit from 'tumor-softening' treatment 2Health News:Many depressed preschoolers still suffer in later school years 2Health News:Many depressed preschoolers still suffer in later school years 3Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 4Health News:Nourish Nutrition and Health Now Accepting Highmark Insurance 2
... Program to Help Students Achieve ... Medical and Dental Education, ... Army Medical,Department has created a new $20,000 Critical Skills Accession ... into the Army,s,F. Edward Hebert Armed Forces Health Professions Scholarship ...
... U.S. Department of,Labor,s Occupational Safety and Health Administration ... to target worksites where,employees are at risk for ... silica threatens nearly two million American employees,annually," said ... Foulke, Jr.,"Under this program, OSHA will work diligently ...
... DNA of the common Black Rat (Rattus rattus) has ... and diseases around the globe. , Studying the mitochondrial ... around the world, an international team of scientists has ... tree, each originating from a different part of Asia. ...
... NEW YORK, Feb. 1 Bobbi Brown Cosmetics ... palette in partnership,with The Heart Truth,s 2008 Red ... Bobbi Brown Cosmetics is an official sponsor for ... performing arts, literature,fashion, business, food, media/journalism, and sports ...
... and urges better pediatric controls , , FRIDAY, Feb. 1 ... or suffering caused by health care -- occur frequently ... research. , These IEs are sometimes serious and often ... Marseille, France. , They looked at 388 newborns admitted ...
... Feb. 1 The globally active precious,metal and ... by purchasing the Interventional Business of Synovis Life,Technologies, ... was,closed on January 31, 2008. With this acquisition, ... people at 5 facilities in the,U.S., Germany, Switzerland ...
Cached Medicine News:Health News:Army Offers New $20,000 Signing Bonus for Medical and Dental School Scholarship Recipients 2Health News:Army Offers New $20,000 Signing Bonus for Medical and Dental School Scholarship Recipients 3Health News:OSHA Establishes a New National Emphasis Program on Silica 2Health News:Globetrotting black rat genes reveal spread of humans and diseases 2Health News:Bobbi Brown Cosmetics Creates Limited-Edition Red Lip Palette in Partnership With The Heart Truth's 2008 Red Dress Collection 2Health News:Unintended Errors Leave Many Newborns Vulnerable 2Health News:Heraeus Strengthens Medical Components Business 2
Freer elevator, double end, 7 1/4", S/B....
... Surgifoam* absorbable gelatin sponge, U.S.P. is ... absorbable sponge intended for hemostatic use ... The sponge is off-white and porous ... to hemostasis, highly favorable surgeon preference ...
8 mm diameter curved probes with suture eyes just back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.6 inches....
Yag Laser System SYL is compact and light-weight. It is CE Mark approved according to MDD....
Medicine Products: